Form 10 Explorer
10-Q
Quarterly Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Jun 30, 2024

Fiscal Year: 2024

View on EDGAR
Balance Sheet
36 line items · 2 periods
XBRL
ItemJun 30, 2024Dec 31, 2023
ASSETS
Current assets:
Cash and Cash Equivalents
3,554,0005,439,000
Cash and Cash Equivalents
6,507,0007,631,000
Accounts Receivable
1,184,000
Other Non-Operating Current Assets
300,000302,000
Total current assets
10,361,00014,556,000
Property, Plant and Equipment
109,000127,000
Operating Lease Right-of-Use Asset
700,000697,000
Intangible Assets
2,491,0002,313,000
Patents
2,382,0002,197,000
Trademarks
109,000116,000
Other Non-Operating Non-Current Assets
2,054,0001,688,000
Total assets
15,715,00019,381,000
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts Payable
5,455,0006,443,000
Other Current Liabilities
799,0001,986,000
Operating Lease Liability, Current
234,000223,000
Short-Term Debt
2,354,000
Total current liabilities
8,842,0008,652,000
Long-term liabilities:
Operating Lease Liability, Non-Current
488,000495,000
Long-Term Debt
283,000
Total liabilities
9,613,0009,147,000
Stockholders’ equity:
Series B Convertible Preferred Stock
689,000
Total Stockholders' Equity
57,00049,000
Total Stockholders' Equity
423,206,000419,004,000
Total Stockholders' Equity
(417,161,000)(409,508,000)
Total stockholders’ equity
6,102,00010,234,000
Series B Preferred Stock - Preferred Stock
689,000
Common Stock
57,00049,000
Additional Paid-in Capital
423,206,000419,004,000
Retained Earnings
(417,161,000)(409,508,000)
Total liabilities and stockholders’ equity
15,715,00019,381,000